CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Tyme Technologies, Inc. - TYME CFD

0.38
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* 0.49
1-Year Change* -2%
Day's Range* 0.48 - 0.48
52 wk Range 0.2187-1.14
Average Volume (10 days) 1.42067
Average Volume (3 months) 28.7169
Market Cap 53.5047
P/E Ratio N/A
Shares Outstanding 172207000
Revenue N/A
EPS -0.14048
Dividend (Yield %) N/A
Beta 0.9045
Next Earnings Date Nov 7, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 26, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
Jan 25, 2022 0.50 0.02 4.17% 0.48 0.52 0.48
Jan 24, 2022 0.50 0.03 6.38% 0.47 0.52 0.45
Jan 21, 2022 0.52 -0.01 -1.89% 0.53 0.54 0.51
Jan 20, 2022 0.53 -0.03 -5.36% 0.56 0.57 0.52
Jan 19, 2022 0.56 0.01 1.82% 0.55 0.57 0.53
Jan 18, 2022 0.55 -0.03 -5.17% 0.58 0.59 0.55
Jan 14, 2022 0.59 0.03 5.36% 0.56 0.60 0.56
Jan 13, 2022 0.57 0.00 0.00% 0.57 0.58 0.56
Jan 12, 2022 0.58 -0.02 -3.33% 0.60 0.60 0.57
Jan 11, 2022 0.59 0.02 3.51% 0.57 0.60 0.56
Jan 10, 2022 0.57 -0.01 -1.72% 0.58 0.59 0.55
Jan 7, 2022 0.58 -0.01 -1.69% 0.59 0.62 0.58
Jan 6, 2022 0.59 -0.03 -4.84% 0.62 0.62 0.57
Jan 5, 2022 0.62 -0.04 -6.06% 0.66 0.66 0.62
Jan 4, 2022 0.66 0.03 4.76% 0.63 0.67 0.62
Jan 3, 2022 0.63 0.05 8.62% 0.58 0.63 0.58
Dec 31, 2021 0.58 -0.01 -1.69% 0.59 0.60 0.58
Dec 29, 2021 0.65 0.00 0.00% 0.65 0.66 0.63
Dec 28, 2021 0.66 0.01 1.54% 0.65 0.67 0.65

Tyme Technologies, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total revenue 0 0 0 0 0 0
Total Operating Expense 15.2068 19.3599 31.7766 25.7604 27.217 25.5136
Selling/General/Admin. Expenses, Total 9.09519 10.5202 14.5862 12.8045 10.1855 9.6321
Research & Development 6.11159 8.83966 14.7195 12.9559 17.0315 13.4441
Operating Income -15.2068 -19.3599 -31.7766 -25.7604 -27.217 -25.5136
Interest Income (Expense), Net Non-Operating 0 0 0.08256 3.75982 -3.99045 1.88754
Other, Net 0 0.39039 -1.28913 0 2.2287 0
Net Income Before Taxes -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Net Income After Taxes -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Minority Interest 0
Net Income Before Extra. Items -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Net Income -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Income Available to Common Excl. Extra. Items -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Income Available to Common Incl. Extra. Items -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Diluted Net Income -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Diluted Weighted Average Shares 84.4546 90.5675 102.354 114.533 134.251 172.207
Diluted EPS Excluding Extraordinary Items -0.18006 -0.20945 -0.32225 -0.19209 -0.21586 -0.1372
Diluted Normalized EPS -0.18006 -0.20945 -0.2981 -0.19209 -0.21586 -0.12304
Unusual Expense (Income) 2.47091 0 2.43738
Revenue 0
Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022
Total revenue 0 0 0 0 0
Total Operating Expense 6.25254 6.65257 5.92852 5.88758 7.04492
Selling/General/Admin. Expenses, Total 2.1928 2.46816 2.4331 2.42429 2.30655
Research & Development 4.05974 4.18441 3.49542 3.46328 2.30099
Operating Income -6.25254 -6.65257 -5.92852 -5.88758 -7.04492
Interest Income (Expense), Net Non-Operating -0.92916 0.70388 0.3638 0.56991 0.23041
Other, Net 0 0.01952 0 0 0
Net Income Before Taxes -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Net Income After Taxes -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Net Income Before Extra. Items -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Net Income -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Income Available to Common Excl. Extra. Items -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Income Available to Common Incl. Extra. Items -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Diluted Net Income -7.1817 -5.92916 -5.56471 -5.31766 -6.81451
Diluted Weighted Average Shares 154.169 172.205 172.207 172.207 172.207
Diluted EPS Excluding Extraordinary Items -0.04658 -0.03443 -0.03231 -0.03088 -0.03957
Diluted Normalized EPS -0.04658 -0.03443 -0.03231 -0.03088 -0.02542
Revenue 0 0 0 0
Dividends per Share - Common Stock Primary Issue 0 0 0
Unusual Expense (Income) 2.43738
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total Current Assets 10.7113 29.7084 16.1391 28.0793 109.657 78.8963
Cash and Short Term Investments 10.483 28.9758 14.3023 26.7004 107.516 74.3509
Cash & Equivalents 10.483 28.9758 14.3023 26.7004 107.516 13.7389
Prepaid Expenses 0.22836 0.73256 1.83679 1.37891 2.14044 4.54539
Total Assets 10.7189 31.0178 17.5166 29.5008 110.263 88.0152
Property/Plant/Equipment, Total - Net 0.00754 0.00324 0.01036 0.15548 0.07547 0.03823
Property/Plant/Equipment, Total - Gross 0.02146 0.02146 0.03701 0.03701
Accumulated Depreciation, Total -0.01393 -0.01822 -0.03183 -0.03701
Total Current Liabilities 3.32707 4.54587 6.21314 5.58179 5.64379 7.3857
Payable/Accrued 2.87697 2.62407 3.33043 2.66661 3.60228 3.4725
Notes Payable/Short Term Debt 0 0.48009 0.59734 0.51812 0 0
Other Current Liabilities, Total 0.4501 0.19303 0.79012 0.54141 0.96613 2.94278
Total Liabilities 3.32707 4.54587 7.84877 10.4757 8.46767 7.93175
Total Long Term Debt 0 0 0 0 0 0
Total Equity 7.39181 26.472 9.66788 19.0251 101.796 80.0834
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.00918 0.01013 0.0104 0.01233 0.01722 0.01722
Additional Paid-In Capital 41.4197 79.2934 95.4722 126.828 238.572 241.031
Retained Earnings (Accumulated Deficit) -33.8621 -52.8316 -85.8147 -107.815 -136.794 -160.42
Other Equity, Total -0.175 -0.54426
Total Liabilities & Shareholders’ Equity 10.7189 31.0178 17.5166 29.5008 110.263 88.0152
Total Common Shares Outstanding 88.2515 101.226 103.946 123.312 172.201 172.207
Other Long Term Assets, Total 1.30623 1.36717 1.26603 0.53099 0
Accrued Expenses 1.24869 1.49525 1.85564 1.07537 0.97041
Other Liabilities, Total 1.63563 4.89391 2.82389 0.54606
Short Term Investments 60.612
Long Term Investments 9.08067
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 109.657 74.6885 77.3799 76.5475 78.8963
Cash and Short Term Investments 107.516 72.6232 75.5104 75.0594 74.3509
Cash & Equivalents 107.516 36.4589 29.2156 20.8022 13.7389
Prepaid Expenses 2.14044 2.06523 1.86946 1.48811 4.54539
Total Assets 110.263 103.098 97.8066 93.0008 88.0152
Property/Plant/Equipment, Total - Net 0.07547 0.06656 0.0574 0.04796 0.03823
Property/Plant/Equipment, Total - Gross 0.03701
Accumulated Depreciation, Total -0.03701
Other Long Term Assets, Total 0.53099 0 0 0 0
Total Current Liabilities 5.64379 4.63152 4.77251 5.45268 7.3857
Payable/Accrued 3.60228 3.44197 3.2426 3.67264 3.4725
Accrued Expenses 1.07537 0.40833 0.78008 1.15187 0.97041
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.96613 0.78122 0.74982 0.62817 2.94278
Total Liabilities 8.46767 6.61569 6.29734 6.31038 7.93175
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 2.82389 1.98416 1.52484 0.8577 0.54606
Total Equity 101.796 96.4825 91.5093 86.6904 80.0834
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.01722 0.01722 0.01722 0.01722 0.01722
Additional Paid-In Capital 238.572 239.222 239.839 240.443 241.031
Retained Earnings (Accumulated Deficit) -136.794 -142.723 -148.288 -153.606 -160.42
Total Liabilities & Shareholders’ Equity 110.263 103.098 97.8066 93.0008 88.0152
Total Common Shares Outstanding 172.201 172.207 172.207 172.207 172.207
Short Term Investments 36.1644 46.2948 54.2573 60.612
Long Term Investments 28.3431 20.3694 16.4053 9.08067
Other Equity, Total -0.03384 -0.05856 -0.1642 -0.54426
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Net income/Starting Line -15.2068 -18.9695 -32.9831 -22.0006 -28.9788 -23.6261
Cash From Operating Activities -5.86113 -11.8793 -20.1161 -19.5603 -23.5645 -21.2428
Cash From Operating Activities 0.00428 0.0043 0.00842 0.00518 0.00518 0
Non-Cash Items 8.07209 7.29895 10.2408 2.44107 5.14359 2.26121
Cash Taxes Paid 0 0 0 0 0 0
Cash Interest Paid 0 0 0.00742 0.11424 0.09713 0.07024
Changes in Working Capital 1.26929 -0.21301 2.61781 -0.00601 0.26551 0.12209
Cash From Investing Activities 0 -0.01554 0 -72.5409
Capital Expenditures 0 -0.01554 0
Cash From Financing Activities 10.2388 30.3721 5.45815 31.9584 104.38 0.00619
Financing Cash Flow Items 0 0.175 0
Issuance (Retirement) of Stock, Net 10.4709 30.1971 5.93824 32.5557 104.899 0.00619
Issuance (Retirement) of Debt, Net -0.2321 0 -0.48009 -0.59734 -0.51812 0
Net Change in Cash 4.37767 18.4928 -14.6735 12.3981 80.816 -93.7775
Other Investing Cash Flow Items, Total -72.5409
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -28.9788 -5.92916 -11.4939 -16.8115 -23.6261
Cash From Operating Activities -23.5645 -5.80934 -10.2803 -14.0354 -21.2428
Cash From Operating Activities 0.00518 0 0 0 0
Non-Cash Items 5.14359 0.14583 0.91297 1.43436 2.26121
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0.09713 0.02126 0.04063 0.05693 0.07024
Changes in Working Capital 0.26551 -0.026 0.30056 1.34173 0.12209
Cash From Financing Activities 104.38 0.00619 0.00619 0.00619 0.00619
Issuance (Retirement) of Stock, Net 104.899 0.00619 0.00619 0.00619 0.00619
Issuance (Retirement) of Debt, Net -0.51812 0 0 0 0
Net Change in Cash 80.816 -71.0576 -78.3008 -86.7143 -93.7775
Cash From Investing Activities -65.2544 -68.0266 -72.685 -72.5409
Other Investing Cash Flow Items, Total -65.2544 -68.0266 -72.685 -72.5409
Financing Cash Flow Items 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Tyme Technologies, Inc. Company profile

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
Industry: Bio Therapeutic Drugs

1 Pluckemin Way - Suite 103
BEDMINSTER
NEW JERSEY 07921
US

Income Statement

People also watch

US100

11,760.60 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0166%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 3.0

XRP/USD

0.40 Price
+0.680% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00339

Oil - Crude

76.62 Price
-1.870% 1D Chg, %
Long position overnight fee -0.0082%
Short position overnight fee -0.0061%
Overnight fee time 22:00 (UTC)
Spread 0.09

BTC/USD

16,592.20 Price
+0.270% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading